A new real-world study from Duke Health gives useful information about lecanemab, a drug for early-stage Alzheimer's disease. The medication removes a protein from the brain to slow down the illness. Researchers tracked more than 230 patients between 2023 and 2025 to see how well clinical trial results match real life.
The study found that about 80 percent of patients continued the treatment for at least one year. Most side effects improved over time without extra treatment. However, about 21 percent of patients stopped the therapy, mostly because of adverse reactions. A main side effect was ARIA, which causes swelling or bleeding in the brain, affecting about 24 percent of patients.
Patients with two copies of a specific gene called APOE ε4 were four times more likely to develop ARIA. Although lecanemab does not cure Alzheimer's disease or reverse memory loss, doctors explain that slowing down the progression helps patients remain independent longer and gives families valuable time together.
Difficult words
- treatment — medical care given to help a patient get better
- adverse — harmful, dangerous, or causing bad effects
- progression — the process of developing or moving forward over time
- independent — able to live or act without help from others
- reaction — an unpleasant physical response to a drug or substancereactions
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it important for medical researchers to study how treatments work in real life compared to clinical trials?
- How can slowing down an illness improve the quality of life for both patients and their families?
Related articles
African leaders call for local funding of medical innovation
A group of African science leaders says Africa must develop and pay for its own medical innovations to improve health and rely less on uncertain international funding. They call for more national investment, reforms and stronger research systems.
New oral drug approved for sleeping sickness
European regulators approved Acoziborole, a single-dose oral treatment for sleeping sickness after successful trials in the DRC and Guinea. Sanofi will donate doses to WHO, but national approvals and vector control are still needed to reach elimination goals.
Targeting inflammation as a way to treat depression
A federally funded review and meta-analysis found that anti-inflammatory treatments reduced depressive symptoms and eased anhedonia in people with depression who had high inflammation. The drugs were not FDA-approved for depression and would be used off-label.
Virtual diet and exercise program helps people with lymphoma
A study tested a virtual diet and exercise program for people getting chemotherapy for lymphoma. The program improved symptoms, attendance was high, and participants had better strength and physical performance during treatment.